Biocon Plays The Biosimilars Card

Keywords for President Park's 3 years in office

Keywords for President Park's 3 years in office

Talking Point: e-Learning To Drive Next Leg Of Growth For Aptech?

Where Will Global GDP Growth Come From In Next Five Years?

Gov't unveils plans to support innovative growth over next five years

Why to expect an increase in economic growth over the next years?

Why earnings growth could see a drastic change over next two years

Expect Cumulative Earnings Growth Can Be 50% Over Next 3 Years, Says Manish Gunwani

DTI projects double-digit growth for PH creative industries in the next 3 years

Granules Confident Of 25% Earnings Growth Over Next 3 Years: MD Chigurupati

Mindtree Confident Of Double-Digit Growth For Next Few Years

Gov't unveils plans to support innovative growth over next five years

Nation View: United Nation report suggest good GDP growth in next two years

Korea's potential growth rate expected to fall to 2.5% for next 4 years

Birla OPUS' Growth Projection in Next 2-3 Years | NDTV Profit

Look to achieve double-digit growth in next 5 years, says Ashish Vohra of Reliance Nippon Life

What is medical interchangeability and how does it apply to Biosimilars?

EU will den Zugang zu Biosimilars für Patienten fördern

Biosimilars: a cheaper yet equally efficient alternative to name-brand medications

Biocon and HealthCare Global In Focus | Earnings Edge | NDTV Profit

Profit Insights | Biocon's Kiran Mazumdar Shaw Exclusive | NDTV Profit

Q1 Review: Biocon's Profit, Margins Fall; Misses Estimates

Kiran Mazumdar Shaw’s multi-billion dollar baby

Q4 Review | Biocon March Quarter Net Profit Soars

Stocks In Focus: Biocon, CG Power and Industrials, LIC & More

Jakson Group Bets On Solar & Sustainability | NDTV Profit

What Women Need To Know About Inheritance | Big Decisions Episode 3 With Bijal Ajinkya

Small & Midcap Outperformance To Reverse? | NDTV Profit

Laurus Labs Q4 Results: CEO Satyanarayana Chava Dissects Numbers | Talking Point | NDTV Profit

What Went Wrong At Kotak Mahindra Bank? | NDTV Profit

Mphasis Q4: Steady Revenue and Profit Growth; Margins Remain Flat | NDTV Profit

Médicament biosimilaire : c'est quoi ?

A $6 Billion Biosimilar Opportunity

Lupin Enters Biosimilar Segment With Etanercept

Your Health Matters: Biosimilar Medication

New treatments options using biosimilars

Korea's biosimilar drug market to nearly double by 2019